PL2439195T3 - Pochodne naftalenokarboksyamidu jako inhibitory kinazy białkowej i deacetylazy histonowej, sposoby ich wytwarzania oraz ich zastosowania - Google Patents

Pochodne naftalenokarboksyamidu jako inhibitory kinazy białkowej i deacetylazy histonowej, sposoby ich wytwarzania oraz ich zastosowania

Info

Publication number
PL2439195T3
PL2439195T3 PL10782884T PL10782884T PL2439195T3 PL 2439195 T3 PL2439195 T3 PL 2439195T3 PL 10782884 T PL10782884 T PL 10782884T PL 10782884 T PL10782884 T PL 10782884T PL 2439195 T3 PL2439195 T3 PL 2439195T3
Authority
PL
Poland
Prior art keywords
inhibitors
protein kinase
preparation methods
histone deacetylase
carboxamide derivatives
Prior art date
Application number
PL10782884T
Other languages
English (en)
Inventor
Xianping Lu
Zhibin Li
Song Shan
Jindi Yu
Zhiqiang Ning
Original Assignee
Shenzhen Chipscreen Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Ltd filed Critical Shenzhen Chipscreen Biosciences Ltd
Publication of PL2439195T3 publication Critical patent/PL2439195T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL10782884T 2009-06-04 2010-03-05 Pochodne naftalenokarboksyamidu jako inhibitory kinazy białkowej i deacetylazy histonowej, sposoby ich wytwarzania oraz ich zastosowania PL2439195T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910143978 2009-06-04
PCT/CN2010/000272 WO2010139180A1 (zh) 2009-06-04 2010-03-05 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
EP10782884.0A EP2439195B1 (en) 2009-06-04 2010-03-05 Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase, preparation methods and uses thereof

Publications (1)

Publication Number Publication Date
PL2439195T3 true PL2439195T3 (pl) 2015-02-27

Family

ID=43261686

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10782884T PL2439195T3 (pl) 2009-06-04 2010-03-05 Pochodne naftalenokarboksyamidu jako inhibitory kinazy białkowej i deacetylazy histonowej, sposoby ich wytwarzania oraz ich zastosowania

Country Status (18)

Country Link
EP (1) EP2439195B1 (pl)
JP (1) JP5484568B2 (pl)
KR (2) KR20140014313A (pl)
CN (1) CN101906076B (pl)
AU (1) AU2010256246B9 (pl)
BR (1) BRPI1011994B8 (pl)
CA (1) CA2763822C (pl)
DK (1) DK2439195T3 (pl)
ES (1) ES2509615T3 (pl)
HR (1) HRP20140717T1 (pl)
MX (1) MX2011012752A (pl)
PL (1) PL2439195T3 (pl)
PT (1) PT2439195E (pl)
RU (1) RU2497809C2 (pl)
SI (1) SI2439195T1 (pl)
UA (1) UA103092C2 (pl)
WO (1) WO2010139180A1 (pl)
ZA (1) ZA201109030B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
CN102260210B (zh) * 2011-05-30 2012-06-27 王立强 蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物的制备方法
CN102603627B (zh) * 2011-05-31 2013-02-06 王立强 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物及其制备方法
CN102850236B (zh) * 2011-06-27 2016-05-18 国药一心制药有限公司 新型苯甲酰胺类组蛋白去乙酰化酶抑制剂及其应用
CN103420923B (zh) * 2012-05-18 2015-08-19 国药一心制药有限公司 4-氨基喹唑啉异羟肟酸类化合物及作为抗肿瘤药物应用
CN103288728A (zh) * 2013-05-17 2013-09-11 华侨大学 一种萘甲酰胺衍生物、其制备方法以及应用
CN103351336A (zh) * 2013-06-28 2013-10-16 华侨大学 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘甲酰胺衍生物及其制备方法
CN103432077A (zh) * 2013-08-21 2013-12-11 北京淦航医药科技有限公司 西达苯胺固体分散制剂
CN104418867B (zh) * 2013-08-26 2016-12-28 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
CN103724260A (zh) * 2013-12-18 2014-04-16 华侨大学 一种苯甲酰胺衍生物及其制备方法和应用
CN104860885B (zh) 2014-02-24 2017-11-17 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
CN103896836A (zh) * 2014-03-20 2014-07-02 华侨大学 N-苯基-6-[(7-氯喹啉-4-氧基)酚醚]-2-萘甲酰胺及其制备方法
CN103923004A (zh) * 2014-04-04 2014-07-16 华侨大学 一种萘甲酰胺衍生物及其制备和应用
CN104030980A (zh) * 2014-06-10 2014-09-10 华侨大学 N-(3-甲氧基-4-氯苯基)-4-[(7-氯-4-喹啉)氨基]苯甲酰胺及其制备和应用
CN105399685B (zh) * 2014-09-16 2018-05-22 深圳微芯生物科技有限责任公司 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
CN104447534A (zh) * 2014-12-04 2015-03-25 厦门大学 6-[(7-氯喹啉-4-氧基)酚醚]-2-萘甲酰胺类衍生物及其制备方法和用途
CN107868044B (zh) 2016-09-27 2020-10-16 深圳微芯生物科技股份有限公司 一种非溶剂化晶体及其制备方法与应用
EP3669869B1 (en) * 2017-04-10 2023-11-22 Shi, Jianyou Drug for treating tumor diseases, and having antibacterial, antivirus and anti-inflammatory effects
CN109985039A (zh) * 2017-12-29 2019-07-09 深圳微芯生物科技股份有限公司 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途
CN110833544B (zh) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
CN109908143B (zh) * 2018-12-18 2021-11-19 厦门大学附属第一医院 西奥罗尼在制备治疗急性髓系白血病药物的新用途
TWI858454B (zh) * 2019-03-25 2024-10-11 大陸商深圳微芯生物科技股份有限公司 西奧羅尼用於小細胞肺癌的治療
JP7423655B2 (ja) 2019-04-03 2024-01-29 プライムジーン（ベイジン）カンパニー リミテッド キノリル含有化合物、医薬組成物およびその使用
CN118846077A (zh) * 2020-03-24 2024-10-29 深圳微芯生物科技股份有限公司 包含蛋白激酶抑制剂和化疗药物的药物组合物及其用途
US12649721B2 (en) 2020-09-23 2026-06-09 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences CSF1R kinase inhibitor and use thereof
CN117377492A (zh) * 2021-05-26 2024-01-09 深圳微芯生物科技股份有限公司 包含蛋白激酶抑制剂的药物组合物及其医药用途
IL321757A (en) 2022-12-28 2025-08-01 Shenzhen Chipscreen Biosciences Co Ltd Naphthylamide compound, and preparation method therefor and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
JP2003528074A (ja) 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
WO2001083450A2 (en) 2000-05-02 2001-11-08 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
CA2465978C (en) * 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
EA009337B1 (ru) 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
ATE536353T1 (de) 2003-08-20 2011-12-15 Vertex Pharma 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
EP1660503A1 (en) * 2003-08-29 2006-05-31 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases

Also Published As

Publication number Publication date
JP5484568B2 (ja) 2014-05-07
CA2763822C (en) 2014-12-09
CN101906076A (zh) 2010-12-08
ZA201109030B (en) 2013-02-27
EP2439195A1 (en) 2012-04-11
WO2010139180A8 (zh) 2012-01-05
CN101906076B (zh) 2013-03-13
AU2010256246A1 (en) 2012-01-12
RU2497809C2 (ru) 2013-11-10
AU2010256246B9 (en) 2014-01-30
BRPI1011994B1 (pt) 2020-04-07
UA103092C2 (ru) 2013-09-10
CA2763822A1 (en) 2010-12-09
KR20120016659A (ko) 2012-02-24
JP2012528800A (ja) 2012-11-15
AU2010256246B2 (en) 2013-04-11
MX2011012752A (es) 2012-03-07
BRPI1011994A2 (pt) 2016-05-10
ES2509615T3 (es) 2014-10-17
DK2439195T3 (da) 2014-09-22
KR101421786B1 (ko) 2014-07-22
EP2439195A4 (en) 2012-10-31
BRPI1011994B8 (pt) 2021-05-25
WO2010139180A1 (zh) 2010-12-09
PT2439195E (pt) 2014-09-10
HRP20140717T1 (hr) 2014-11-21
KR20140014313A (ko) 2014-02-05
EP2439195B1 (en) 2014-07-16
SI2439195T1 (sl) 2014-12-31

Similar Documents

Publication Publication Date Title
ZA201109030B (en) Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase,preparation methods and uses thereof
IL249594A0 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
ZA201207856B (en) Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
ZA201206063B (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
EP2265590B8 (en) Selective inhibitors of histone deacetylase
TWI562992B (en) Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
IL214822A0 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL216132A (en) Heterocyclic carboxamide diamine compounds, their uses and their medicinal products and inhibitors
SI2262803T1 (sl) Polisubstituirani derivati 2-aril-6-fenil-imidazo(1,2-alfa)piridinov, njihova priprava in njihova terapevtska uporaba
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
EP2536283B8 (en) Phenyl-heteroaryl derivatives and methods of use thereof
EP2139850A4 (en) Histone deacetylase INHIBITORS
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL222361A (en) Demethylase-1 inhibitors for lysine and their use
AP2013006902A0 (en) e and their use as HSD 1 inhibitors A-S)-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4A,9,9Crystalline forms of hydrochloride salt of (4A-R,9A-hexahydro-1H-indeno[2,1-B]pyridine-6-carbonitril
IL223514A0 (en) Benzamide derivatives and their use as hsp90 inhibitors
IL236686A0 (en) Inhibitors of histone deacetylase and compositions and methods of using them
EP2424533A4 (en) SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
EP2734510B8 (en) Activators of class i histone deacetylases (hdacs) and uses thereof
HK1191805A (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1177101A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof